Skip to content
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Ophthalmology

The Biology and Genetics of arPEO: Understanding the Root Cause

At a Glance

arPEO is caused by inherited changes in both copies of a nuclear gene that maintains mitochondrial DNA. When mitochondrial DNA is lost or depleted, the energy-hungry eye muscles can develop slowly worsening drooping eyelids and limited movement, sometimes with symptoms beyond the eyes.

Understanding the biology of arPEO is like looking at a power plant where the blueprints for the generators have been damaged. While the problem shows up in your eyes, the root cause is actually located in the “master blueprints” (your nuclear DNA) that manage your cell’s energy-producing mitochondria [1].

The Genetic Blueprint

Every cell in your body has two types of DNA. Your nuclear DNA (nDNA) contains the vast majority of instructions for building and maintaining your body, including replicating energy structures, while your mitochondrial DNA (mtDNA) specifically encodes a small subset of energy-production components [1].

In arPEO, you have inherited two faulty copies of a specific nuclear gene—one from each parent [2]. These nuclear genes are responsible for “maintenance duty.” When they are broken, they cannot properly repair or replicate the mtDNA [3]. This leads to mtDNA deletions (pieces of the energy blueprint go missing) or mtDNA depletion (the overall amount of energy blueprints drops) [1]. Because the muscles that move your eyes are some of the most energy-hungry in the body, they are usually the first to fail when these “power plant” blueprints are damaged [4].

Common nuclear genes linked to arPEO include:

  • POLG: This gene makes the “copy machine” (DNA polymerase γ) for mtDNA. It is the most common cause of arPEO and can cause a wide range of symptoms [2][5].
  • RRM2B: This gene helps supply the “ink” (nucleotides) needed to write new mtDNA [6].
  • RNASEH1: This gene helps clean up the mtDNA replication process; when it is faulty, the “copying” gets stuck [7].

Pure PEO vs. PEO-Plus

Doctors use two categories to describe how arPEO affects a person:

  1. Pure PEO: This is “isolated” ocular myopathy. The symptoms are limited mostly to the eye muscles (drooping lids and limited movement) [8].
  2. PEO-Plus: This means the mitochondrial defect is causing symptoms beyond the eyes. This can include ataxia (balance issues), peripheral neuropathy (numbness or tingling in hands and feet), hearing loss, or difficulty swallowing (dysphagia) [5][9][10].

It is important to know that a person can start with “Pure PEO” and develop “Plus” symptoms many years later as the mitochondrial damage slowly accumulates in other high-energy tissues like the brain and nerves [11].

Avoiding the “Diagnostic Trap”

Because arPEO is rare and its symptoms are shared with other conditions, in one specific surgical referral cohort roughly 78% of patients are initially misdiagnosed [12]. The most common “mimics” include:

Ocular Myasthenia Gravis (OMG)

OMG is an autoimmune condition where the signal between nerves and muscles is blocked.

  • How they are different: OMG symptoms fluctuate—they get much worse when you are tired and better after rest [13]. In arPEO, the weakness is constant and very slowly worsens over years, rather than hours.
  • Testing: Doctors use an ice pack test (placing ice on the eyelid to see if it temporarily lifts) or blood tests for specific antibodies to identify OMG [14]. A negative result does not completely exclude OMG, but these pieces help build the clinical evaluation.

Congenital Ptosis

This is a drooping eyelid present from birth due to a simple muscle malformation.

  • How they are different: Congenital ptosis does not get worse over time and does not typically affect eye movement (ophthalmoplegia) [12]. Doctors often look at old family photos to see if your eyelids were always droopy or if it is a new, progressive change.

Oculopharyngeal Muscular Dystrophy (OPMD)

This is another genetic muscle disorder that causes drooping lids and difficulty swallowing.

  • How they are different: A doctor will use clinical assessment and genetic testing for the PABPN1 gene, though a muscle biopsy or an MRI can provide pieces of the evaluation [13][15]. A biopsy for OPMD would show unique protein clumps called “nuclear aggregates” that aren’t found in arPEO, but findings can overlap [16].

By identifying the specific gene involved and ruling out these mimics, you and your doctor can create a more accurate roadmap for your future care.

Common questions in this guide

What causes autosomal recessive progressive external ophthalmoplegia?
arPEO occurs when a person inherits a harmful change in both copies of a nuclear gene, with one copy coming from each parent. The affected gene helps maintain mitochondrial DNA, so defects can lead to mitochondrial DNA deletions or depletion and gradually weaken the energy-hungry muscles that move the eyes.
What does biallelic mean on an arPEO genetic test?
Biallelic means that both copies of a gene carry relevant genetic changes—one inherited from each parent. This inheritance pattern is consistent with an autosomal recessive condition, but a genetics professional must determine whether the specific changes are disease-causing.
Which genes are linked to arPEO?
POLG is the most common arPEO-associated gene described on this page. RRM2B and RNASEH1 are also linked to arPEO, and other nuclear genes may be involved. Genetic testing can help identify the gene responsible in an individual.
What is the difference between pure PEO and PEO-plus?
Pure PEO mainly affects the muscles that control the eyes, causing drooping eyelids and limited eye movement. PEO-plus includes symptoms outside the eyes, such as balance problems, peripheral nerve symptoms, hearing loss, or difficulty swallowing. A person may begin with pure PEO and develop additional symptoms later.
How is arPEO different from ocular myasthenia gravis?
Ocular myasthenia gravis often fluctuates, becoming worse with fatigue and better after rest, while arPEO usually causes eye weakness that progresses slowly over years. Clinicians may use an ice pack test and antibody blood tests when evaluating for ocular myasthenia gravis, along with the medical history and examination. A negative result does not completely rule it out.
Can arPEO be mistaken for congenital ptosis or OPMD?
Yes. Congenital ptosis is usually present from birth, does not progressively worsen, and typically does not limit eye movement. Oculopharyngeal muscular dystrophy can also cause drooping eyelids and swallowing difficulty, so clinical assessment and genetic testing, including PABPN1 testing when appropriate, can help distinguish it from arPEO.

Get notified when new evidence is published on Autosomal recessive progressive external ophthalmoplegia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (16)
  1. 1

    Mitochondrial DNA maintenance defects.

    El-Hattab AW, Craigen WJ, Scaglia F

    Biochimica et biophysica acta. Molecular basis of disease 2017; (1863(6)):1539-1555 doi:10.1016/j.bbadis.2017.02.017.

    PMID: 28215579
  2. 2

    Deep sequencing of mitochondrial DNA and characterization of a novel POLG mutation in a patient with arPEO.

    Hedberg-Oldfors C, Macao B, Basu S, et al.

    Neurology. Genetics 2020; (6(1)):e391 doi:10.1212/NXG.0000000000000391.

    PMID: 32042919
  3. 3

    MtDNA-maintenance defects: syndromes and genes.

    Viscomi C, Zeviani M

    Journal of inherited metabolic disease 2017; (40(4)):587-599 doi:10.1007/s10545-017-0027-5.

    PMID: 28324239
  4. 4

    Changing faces of mitochondrial disease: autosomal recessive POLG disease mimicking myasthenia gravis and progressive supranuclear palsy.

    Elwan M, Schaefer AM, Craig K, et al.

    BMJ neurology open 2022; (4(2)):e000352 doi:10.1136/bmjno-2022-000352.

    PMID: 36518302
  5. 5

    POLG-related disorders and their neurological manifestations.

    Rahman S, Copeland WC

    Nature reviews. Neurology 2019; (15(1)):40-52 doi:10.1038/s41582-018-0101-0.

    PMID: 30451971
  6. 6

    Identification of two novel RRM2B variants associated with autosomal recessive progressive external ophthalmoplegia in a family with pseudodominant inheritance pattern.

    Restrepo-Vera JL, Rovira-Moreno E, Ramón J, et al.

    Journal of human genetics 2023; (68(8)):527-532 doi:10.1038/s10038-023-01144-2.

    PMID: 36959467
  7. 7

    RNASEH1 Mutations Impair mtDNA Replication and Cause Adult-Onset Mitochondrial Encephalomyopathy.

    Reyes A, Melchionda L, Nasca A, et al.

    American journal of human genetics 2015; (97(1)):186-93.

    PMID: 26094573
  8. 8

    Revisiting mitochondrial ocular myopathies: a study from the Italian Network.

    Orsucci D, Angelini C, Bertini E, et al.

    Journal of neurology 2017; (264(8)):1777-1784 doi:10.1007/s00415-017-8567-z.

    PMID: 28695364
  9. 9

    Clinicopathologic and molecular spectrum of RNASEH1-related mitochondrial disease.

    Bugiardini E, Poole OV, Manole A, et al.

    Neurology. Genetics 2017; (3(3)):e149 doi:10.1212/NXG.0000000000000149.

    PMID: 28508084
  10. 10

    Clinical, Histological, and Genetic Features of 25 Patients with Autosomal Dominant Progressive External Ophthalmoplegia (ad-PEO)/PEO-Plus Due to TWNK Mutations.

    Bermejo-Guerrero L, de Fuenmayor-Fernández de la Hoz CP, Serrano-Lorenzo P, et al.

    Journal of clinical medicine 2021; (11(1)) doi:10.3390/jcm11010022.

    PMID: 35011763
  11. 11

    Novel and recurrent nuclear gene variations in a cohort of Chinese progressive external ophthalmoplegia patients with multiple mtDNA deletions.

    Hou Y, Zhao X, Xie Z, et al.

    Molecular genetics & genomic medicine 2022; (10(5)):e1921 doi:10.1002/mgg3.1921.

    PMID: 35289132
  12. 12

    Type and Frequency of Misdiagnosis and Time Lag to Diagnosis in Patients with Chronic Progressive External Ophthalmoplegia.

    Karimi N, Ghahvehchian H, Keyhani A, et al.

    Journal of ophthalmic & vision research 2024; (19(3)):334-339 doi:10.18502/jovr.v19i3.13998.

    PMID: 39359531
  13. 13

    Clinical and imaging clues to the diagnosis and follow-up of ptosis and ophthalmoparesis.

    Keene KR, Kan HE, van der Meeren S, et al.

    Journal of cachexia, sarcopenia and muscle 2022; (13(6)):2820-2834 doi:10.1002/jcsm.13089.

    PMID: 36172973
  14. 14

    Chronic mimics of myasthenia gravis: a retrospective case series.

    Harrison P, Barton J, Winkel A

    Neuromuscular disorders : NMD 2023; (33(3)):250-256 doi:10.1016/j.nmd.2023.01.006.

    PMID: 36753801
  15. 15

    Eye Muscle MRI in Myasthenia Gravis and Other Neuromuscular Disorders.

    Keene KR, Notting IC, Verschuuren JJGM, et al.

    Journal of neuromuscular diseases 2023; (10(5)):869-883 doi:10.3233/JND-230023.

    PMID: 37182896
  16. 16

    Intranuclear Aggregates Precede Clinical Onset in Oculopharyngeal Muscular Dystrophy.

    van der Sluijs BM, Raz V, Lammens M, et al.

    Journal of neuromuscular diseases 2016; (3(1)):101-109 doi:10.3233/JND-150118.

    PMID: 27854203

This page explains the biology, inheritance, and diagnostic clues of arPEO for informational purposes only and does not constitute medical advice. An ophthalmologist, neurologist, or genetics professional should interpret your symptoms and test results and discuss your care.